Adaptive Biotechnologies (NASDAQ: ADPT) reported Q3 EPS of ($0.27), $0.01 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $26.3 million versus the consensus estimate of $23.58 million.

Cash, cash equivalents and marketable securities was $851.5 million as of September 30, 2020.

For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.